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ABSTRACT
The treatment of steroid-refractory acute graft-versus-host disease (aGVHD) remains a clinical challenge, for
which no standard therapy exists. Alemtuzumab is a humanized anti-CD52monoclonal antibody (mAb) that has
been successfully used as part of conditioning regimens for hematopoietic stem cell transplantation (HSCT) to
prevent GVHD. The purpose of this study was to evaluate the safety and efficacy of alemtuzumab in treating
steroid-refractory aGVHD ($grade II) following HSCT. Eighteen patients received subcutaneous alemtuzu-
mab 10 mg daily on 5 consecutive days. Response was assessed at day 28 following initiation of alemtuzumab.
Eight patients had grade II aGVHD, 8 had grade III, and 2 had grade IV. The main organ involved was the liver
in 4 patients, gastrointestinal (GI) tract in 5, skin in 3, skin and liver in 3, and skin and GI tract in 3. Fifteen pa-
tients (83%) responded to alemtuzumab, including 6 (33%) with complete response. All 3 unresponsive patients
died of GVHD. Ten of 15 responders are alive at median follow-up of 11 months (range: 3-24). Infections oc-
curred in 14 patients, including cytomegalovirus (CMV) reactivation in 11. Grade 3 neutropenia and thrombo-
cytopenia occurred in 6 and 4 patients, respectively. Alemtuzumab was well tolerated, and induces promising
response rates in steroid-refractory aGVHD.
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Graft-versus-host disease (GVHD) remains an
important cause of mortality of allogeneic hematopoi-
etic stem cell transplantation (HSCT). The incidence
of acute GVHD (aGVHD) may vary from 20% to
70%, depending on several factors [1-2]. Corticoste-
roids are the current standard initial treatment for
aGVHD, with approximately 50% of patients achiev-
ing an initial response [3-5]. However, no consensus
exists on the optimal treatment of patients who are
unresponsive or refractory to steroid therapy. To
date, a number of therapeutic agents have been evalu-
ated for the treatment of steroid-refractory GVHD,10including high-dose corticosteroids, antithymocyte
globulin (ATG), mycophenolate mofetil (MMF), ta-
crolimus, sirolimus, pentostatin, etanercept, and a va-
riety of monoclonal antibodies (mAbs) [6-14].
Alemtuzumab (Campath-1H) is an unconjugated,
humanized IgG1 kappamAb that targets the CD52 an-
tigen expressed on T and B lymphocytes, monocytes,
monocyte-derived dendritic cells, macrophages, and
eosinophils [15-20]. The Campath-1 family of anti-
bodies was initially developed in the early 1980s as T
cell-depleting (TCD) agents to prevent GVHD in
the allogeneic HSCT setting [18,21]. Alemtuzumab
is currently indicated for the treatment of patients
with fludarabine-refractory B cell chronic lymphocytic
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gest the potential role of alemtuzumab in minimizing
GVHDwhen used as part of the conditioning regimen
for allogeneic HSCT [23-27]. In addition, alemtuzu-
mab has been used successfully to treat established
steroid-refractory, severe aGVHD, although only
anecdotal data are available [28-30]. Based on these
data, we conducted a prospective clinical study to eval-
uate the safety and efficacy of alemtuzumab in the
treatment of steroid-refractory aGVHD in a cohort
of 18 allografted patients.
PATIENTS AND METHODS
Eligibility Criteria
Patients were eligible if they had received allo-
HSCT from either family donors or unrelated cord
blood cells, and had a diagnosis of $ grade II
aGVHD refractory to corticosteroid therapy, as de-
fined by the Consensus criteria [31]. Patients with
uncontrolled infections, cardiac failure, or serum
creatinine $2 mg/dL or who were receiving immu-
nosuppressive agents other than calcineurin inhibi-
tors and corticosteroids were excluded from this
trial. Patients in corticosteroid therapy who initially
responded but recurred with their first taper were
not eligible. All patients provided written informed
consent, and the study protocol was approved by
the local Ethics Committee.
Diagnosis of Steroid-Refractory GVHD and
Evaluation of Response
The initial evaluation and grading of aGVHD was
primarily based on clinical findings. Diagnosis was
supported by skin, liver, or gastrointestinal (GI) tract
biopsy results whenever indicated and clinically possi-
ble. Patients had received initial treatment for GVHD
with corticosteroids given at a dose equivalent to 2mg/
kg of MP. Steroid-refractory GVHD was defined as
nonresponse to corticosteroids administered for at
least 5 consecutive days or progression after 48 hours
of therapy. Twice a week GVHD organ stage scores,
overall clinical grade, and relevant differential diagno-
sis were recorded. Responses were assessed for each in-
volved organ. Complete response (CR) was defined as
the complete resolution of GVHD at day 28. Partial
response (PR) was defined as improvement in at least
1 organ by at least 1 full stage in the absence of pro-
gression in any other organ, allowing for a decrease
in the dose or discontinuation of corticosteroids. No
response (NR) was defined as no reduction in any
GVHD organ staging within 14 days or progression
of GVHD. Toxicity was graded according to the
National Cancer Institute Common Toxicity Criteria
version 3.0.Alemtuzumab Treatment and Anti-Infective
Prophylaxis
Alemtuzumab was administered subcutaneously at
a dose of 10mg daily for 5 consecutive days. One infant
patient who weighed 10 kg received a lower dose,
a total of 15 mg divided across 5 consecutive days.
All patients received alemtuzumab as second-line ther-
apy. The administration of cyclosporine (CsA) contin-
ued during alemtuzumab treatment, and in patients
achieving a response, corticosteroids were slowly
tapered, by a 25% reduction in dose every week.
All patients received anti-infective prophylaxis at the
start of GVHD treatment, including trimethoprim-
sulfamethoxazole for Pneumocystis jirovecii pneumonia,
fluconazole, or itraconazole for fungal infections, and
acyclovir for herpes virus reactivation. Cytomegalovirus
(CMV) infection was monitored weekly by CMV pp65
antigenemia testing; if the test result became positive,
patients were treated preemptively with valganciclovir.
Statistical Analysis
Patients responsive and unresponsive to alemtuzu-
mab treatment were compared on the basis of their
clinical characteristics. Categoric variables were com-
pared using Fisher’s exact test, and continuous values
were compared using the Student’s t-test. Survival
analysis was estimated according to the Kaplan-Meier
method.
RESULTS
Patient Characteristics
All HSCT procedures were performed at the
Hospital Universitario in Monterrey and Centro de
Hematologıa y Medicina Interna de Puebla. Eighteen
patients were eligible for this trial between November
2004 and February 2007, all of whom were evaluable
for efficacy and safety. Baseline patient characteristics
are summarized in Table 1. The main organ involved
was the liver in 4 patients, GI tract in 5, skin in 3,
skin and liver in 3, and skin and GI tract in 3.The me-
dian age of the patients was 37 years (range: 1-59), and
10 patients (56%) had grade III or IV aGVHD. No
prior therapy other than corticosteroids and CsA was
used. The median time to onset of aGVHD was 45
days (range: 14-180), with 8 patients developing late-
onset aGVHD (after day 100) as defined by the recent
NIHWorking Group report [32]. Myeloablative con-
ditioning regimen was used in 1 patient and a fludara-
bine-based reduced-intensity conditioning regimen
was used in 17 patients [33-35]. Seventeen patients
had received peripheral blood stem cells (PBSCs) ob-
tained from HLA-identical siblings, and 17 patients
received GVHD prophylaxis with CsA 3-5 mg/kg in
combination with a short course of methotrexate
(MTX) on days 1, 3, and 5 or 6 following HSCT.
One patient received unrelated cord blood cells, 5/6
12 D. Gomez-Almaguer et al.HLA compatible, and this patient received GVHD
prophylaxis with CsA without MTX. No donor lym-
phocyte infusion (DLI) was used in any patient.
Response
Fifteen of the 18 patients (83%) responded to
alemtuzumab. Six patients (33%) achieved CR, and 9
patients (50%) achieved PR. Five of the 6 patients
with CR maintained CR without additional therapy
with a median duration of 8 months, and 1 developed
disease flare after steroid withdrawal after being in
CR for 2months; this patient was treated with a second
course of alemtuzumab and PR was observed. Among
4 of the 6 patients who achieved CR, the main organ
involved was the GI tract. Responses by grade of
GVHD at study entry and stage of organ involvement
are listed in Table 2. Patients with CR or PR were able
to decrease the steroid dose by 60% at 28 days of treat-
ment. Two of the 9 patients who achieved PR received
Table 1. Baseline Clinical Characteristics
Characteristics No. of patients (%)
Age, years
Median 37
Range 1-59
Sex
Female 11 (61)
Male 7 (39)
Diagnosis
Acute myelogenous leukemia (AML) 5 (28)
Acute lymphocytic leukemia (ALL) 2 (11)
Chronic myelogenous leukemia (CML) 5 (28)
Multiple myeloma (MM) 2 (11)
Chronic lymphocytic leukemia (CLL) 1 (5.5)
Non-Hodgkin lymphoma (NHL) 1 (5.5)
Myelodysplastic syndrome (MDS) 1 (5.5)
Langerhans’ cell histiocytosis (LCH) 1 (5.5)
Donor
HLA-identical sibling 17 (94)
Unrelated cord blood 1 (6)
Conditioning regimen
Reduced intensity (RIC) 17 (94)
Myeloablative 1 (6)
Source of stem cell
Peripheral blood 17 (94)
Cord blood 1 (6)
GVHD prophylaxis
CsA 1 methotrexate 17 (94)
CsA 1 prednisone 1 (6)
GVHD grade
II 8 (44)
III 8 (44)
IV 2 (11)
Main organ involved
Liver 4
GI tract 5
Skin 3
Skin and liver 3
Skin and GI tract 3
CsA indicates cyclosporine; GVHD, graft-versus-host disease; GI,
gastrointestinal.additional therapy with anti-CD20 antibody and tha-
lidomide. At the time of last follow-up, 8 of the 15 re-
sponders were receiving a median steroid dose of 20
mg on alternate days. Alemtuzumab treatment failed
in 3 patients; in 2 of these cases, the primary organs in-
volved were the bowel and skin, and in the remaining
patient, the primary organ affected was the liver. In
this group of nonresponding patients, steroid therapy
was continued at the standard 2 mg/kg/day dose. Re-
sults from the univariate analyses of clinical character-
istics between responders and nonresponders showed
no differences in the main organ involved, GVHD
grade, and time between HSCT and GVHD onset.
Survival
Ten of the 18 patients are still alive at a median fol-
low-up of 11 months (range: 3-24) after alemtuzumab
treatment. Survival curves after treatment with alem-
tuzumab are shown in Figure 1. Actual median survival
for the patients with PR and NR are 8 and 2 months,
respectively. The 3 patients not responding to alemtu-
zumab died of GVHD at 25, 40, and 90 days after ini-
tiation of therapy. The 5 other deaths were attributed
to disease relapse, bronchiolitis obliterans, and infec-
tious complications. Among the 6 patients achieving
CR, 1 patient relapsed of underlying disease 9 months
after alemtuzumab therapy and is receiving salvage
therapy. Extensive chronic GVHD (cGVGD) has
occurred in 4 of the 10 surviving patients, and 1 other
patient has developed limited cGVHD. Five patients
showed no signs of cGVHD.
Safety
After a median follow-up of 9 months (range: 2-23)
14 patients (78%) had 1 or more infectious episodes; 2
patients developed septicemia followed by multiorgan
system failure and died 60 and 90 days after initiation
of alemtuzumab treatment. One patient had fatal
pneumonia of bacterial origin, which developed 6
months after alemtuzumab therapy, and 2 additional
patients developed bacterial pneumonia requiring hos-
pital admission but responded to antibiotic treatment.
These 3 patients previously received valganciclovir be-
cause of asymptomatic CMV reactivation, all resolved
before pneumonia developed. Pulmonary tuberculosis
was identified early in 1 patient and was successfully
treated with broad-spectrum antibiotics. Asymptom-
atic CMV reactivation occurred in 11 patients docu-
mented by positive antigenemia requiring preemptive
ambulatory valganciclovir therapy. No invasive fungal
infections were observed.
Adverse events such as chills, low-grade fever, and
headache were observed in 5 patients. Grade 3 neutro-
penia occurred in 6 patients, and grade 3 thrombocyto-
penia in 4 patients. No lymphoproliferative disorders
have been observed in this group of patients.
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Patient
Age/Sex Diagnosis
GVHD Stage
(Skin-Liver-Gut)
Alemtuzumab
Start (Day Post-SCT)
GVHD
Grade
Response,
Day 28
Current Status
(Day Post-Alemtuzumab*)
27/F AML 1-0-1 23 II PR D, sepsis (60)
25/M ALL 2-0-1 49 II PR D, sepsis (90)
27/F CML 1-0-1 26 II NR D, GVHD (25)
53/F CML 3-0-0 115 II PR cGVHD (698)
55/F CML 3-0-0 110 II PR cGVHD(515)
33/M NHL 2-0-4 42 III NR D, GVHD (40)
57/M CML 2–2-1 128 III PR D, relapse (547)
18/M AML 2-3-0 43 III PR D, infection (210)
15/M AML 1-1-0 158 II PR D, cGVHD (450)
59/F MM 0-1-4 105 IV CR No GVHD (560)
53/M MDS 2-4-0 183 IV NR D,GVHD (90)
1/F LCH 2-1-3 19 III CR No GVHD (420)
53/F AML 3-0-0 185 II CR cGVHD (300)
16/F ALL 2-3-0 108 III CR No GVHD (180)
57/F CLL 0-0-3 40 III CR No GVHD (180)
21/F AML 3-1-0 45 III PR cGVHD (65)
43/F MM 1-0-4 22 III CR No,GVHD (90)
38/F CML 3-1-0 43 II PR cGVHD (65)
AML indicates acute myelogenous leukemia; ALL, acute lymphocytic leukemia; CML, chronic myelogenous leukemia; MM,multiple myeloma;
MDS, myelodysplastic syndrome; LCH, Langerhans’ cell histiocytosis; PR, partial response; CR, complete response; NR, no response; D,
dead; GVHD, graft-versus-host disease; cGVHD, chronic GVHD.
*Day after alemtuzumab.Lymphocyte counts dropped during the first week af-
ter alemtuzumab treatment and remained low (\500
cells/mL) for the subsequent 2 to 8 weeks (mean dura-
tion of 6 weeks).
DISCUSSION
The treatment of steroid-refractory GVHD re-
mains a therapeutic challenge. Results from recent
studies for salvage therapy after steroid failure are
summarized in Table 3 [9,11-13,36-42]. Treatment
with alemtuzumab therapy induces an overall response
rate of 83% and a CR rate of 33%, which is favorable
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Figure 1. Kaplan-Meier plot of overall survival based on response to
alemtuzumab therapy.or comparable to other agents currently under investi-
gation. Bordigoni et al. [36] recently found a response
rate of 90% after daclizumab administration, which
was higher than 83% demonstrated in our trial; of
note, few patient suffered from severe grades III-IV
Table 3. Summary of Studies for Steroid-Refractory GVHD
Agent N
Overall
Response or
Improvement Study
Antithymocyte
globulin
79 54% MacMillan et al., 2002 [11]
47 57% MacMillan et al., 2007 [41]
ABX-CBL
(anti-CD147)
48 56% MacMillan et al., 2007 [41]
Mycophenolate
mofetil
10 60% Krejci et al., 2005 [40]
Pentostatin 23 74% Bolanos-Meade et al.,
2005 [9]
Etanercept 13 46% Busca et al., 2007 [37]
Denileukin
diftitox
30 71% Ho et al, 2004 [39]
Basiliximab
(anti–IL-2
receptor)
23 83% Schmidt-Hieber et al.,
2005 [42]
Dacluzimab
(anti-CD25)
43 51% Przepiorka et al, 2000 [13]
62 90% Bordigoni et al., 2006 [36]
Infliximab
(anti–TNF-a)
32 59% Patriarca et al, 2004 [12]
Visilizumab
(anti-CD3)
44 32% Carpenter et al., 2005 [38]
TNF-a indicates tumor necrosis factor-a; GVHD, graft-versus-host
disease.
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56% of them had steroid-dependent aGVHD.
In our study, notably, treatment with alemtuzu-
mab resulted in the tapering of steroid therapy in the
majority of responding patients, by at least 60% of
the initial steroid dose after 28 days from treatment
initiation. Furthermore, our study is 1 of the first to
examine salvage therapy of late-onset (.100 days)
aGVHD. In the present study, 8 patients developed
acute manifestations of GVHD beyond day 100 from
HSCT, 6 of whom achieved PR. Recently the NHI
Consensus Conference recognized a late aGVHD
(after day 100); we included this group of patients
with a clinical picture of aGVHD who should be
treated with a shorter treatment interval of more inten-
sive immunosupression to control acute inflammatory
manifestations. Although results from the univariate
analysis suggest that none of the clinical characteristics
examined were predictive of response to alemtuzumab
therapy, the number of patients in this study was small.
Hence, these results will require further investigation
in a larger clinical trial. In our centers the use of
matched unrelated HSCT is done using only cord
blood cells, and occasionally we use mismatched
HSCT; therefore, only 1 patient who received unre-
lated cord blood cells was included.
As expected, infections were a common complica-
tion of alemtuzumab therapy, emphasizing the need to
adhere to anti-infective prophylaxis and close monitor-
ing for infections. With a median follow-up of 9
months (range: 2-23), 3 patients developed infectious
complications and died, all of whom had PR and re-
mained dependent on corticosteroid therapy. CMV
reactivation was common, and most incidences devel-
oped shortly after lymphocyte nadir, which occurred
between weeks 2 and 4 after initiation of alemtuzumab.
All patients with CMV reactivation were successfully
treated with valganciclovir; importantly, no progres-
sion to CMV disease was observed.
Treatment with alemtuzumab was well tolerated,
with only 5 patients developing headache, low-grade
fever, and/or chills after the first dose. None of the pa-
tients developed injection-site skin reactions. Transient
cytopenia occurred in 6 patients; thrombocytopenia
was most common after 2 weeks, and neutropenia after
3 weeks of alemtuzumab therapy. No patient required
blood component transfusions or growth factor sup-
port. In the majority of patients, cytopenias resolved
within 6 weeks of onset. Lymphopenia, which is attrib-
utable to the direct consequence of the pharmacologic
action of alemtuzumab, was themost common hemato-
logic toxicity. Epstein-Barr virus (EBV)-related lym-
phoproliferative disorders were not observed in this
study. Although therapeutic agents that may affect T
cell function after allogeneic HSCT raise concerns
for engraftment and control of disease, none of the pa-
tients in our study developed graft rejection; in the 2patients with relapse of underlying disease, 1 had
ongoing GVHD and the other maintains complete
chimerism without signs of GVHD.
The results of this study suggest that subcutaneous
alemtuzumab can be safely administered in patients
with steroid-refractory aGVHD, and that it is associ-
ated with a promising response rate. Further studies
are warranted to confirm our findings in a larger pa-
tient population and also in the setting of unrelated
HSCT, in order to determine the optimal dose and
duration of treatment and to explore the possibility
of a maintenance schedule.
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